Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S319100
Reexamination Certificate
active
07968581
ABSTRACT:
Novel compounds are disclosed that have a Formula represented by the following:wherein X, R1, R2a, R2b, R2c, R3aR3b, R4a, R4b, R4c, and m1 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cachexia, osteoporosis, sarcopenia, a decline in libido and/or sexual dysfunction.
REFERENCES:
patent: 4753957 (1988-06-01), Chan
patent: 4873256 (1989-10-01), Coussediere et al.
patent: 4992443 (1991-02-01), Chelen
patent: 5750553 (1998-05-01), Claussner et al.
patent: 6355664 (2002-03-01), Kelly et al.
patent: 2003/0195238 (2003-10-01), Gil et al.
patent: 2004/0202825 (2004-10-01), Malhotra
patent: 2855770 (1978-12-01), None
patent: 0091596 (1983-03-01), None
patent: 0572191 (1993-05-01), None
patent: 0760239 (1996-08-01), None
patent: 0945441 (1999-09-01), None
patent: 0966447 (1999-12-01), None
patent: 01090114 (1989-06-01), None
patent: 02019363 (1990-01-01), None
patent: 06135937 (1994-05-01), None
patent: 95/29909 (1995-11-01), None
patent: 97/19064 (1997-05-01), None
patent: 98/39303 (1998-11-01), None
patent: 98/57633 (1998-12-01), None
patent: 01/10799 (2001-02-01), None
patent: 01/85685 (2001-11-01), None
patent: 02/14865 (2002-02-01), None
patent: 2007/047146 (2007-04-01), None
patent: 2007/137874 (2007-12-01), None
Angel—1987—Mol Cell Biol—2256, 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-fla.
Claessens—1996—J Biol Chem—271—19013, The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors.
Davison—2003—J Steroid Biochem Mol Biol—85—363, Androgens in women.
Hourdé—2008—Acta Physiol—195—471, Androgen replacement therapy improves function in male rat muscles independently of hypertrophy and activation of the Akt/mTOR pathway.
Kaufman 2005—Endocr Rev—26—833, The decline of androgen levels in elderly men and its clinical and therapeutic implications.
Kun—2003—Am J Physiol Endocrinol Metab—285—E363, Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression.
Liu—2004—J Clin Endocrinol Metab—89—4789, The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations.
Tilley—1989—PNAS—86—327, Characterization and expression of a cDNA encoding the human androgen receptor.
Molander—1995—J Org Chem—60—872, Stereochemical Investigations of Samarium(I1) Iodide-Promoted 5-Exo and 6-Ex0 Ketyl-Olefin Radical Cyclization Reactions.
Blanqué Roland
Deprez Pierre
Jagerschmidt Catherine
Lefrançois Jean-Michel
Namour Florence Sylvie
Galapagos NV
Klauber & Jackson LLC
Saeed Kamal
LandOfFree
Imidazolidine compounds as androgen receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolidine compounds as androgen receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidine compounds as androgen receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654218